Literature DB >> 1249812

Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1.

A H Khan, J S Driscoll.   

Abstract

A series of 3,6-substituted 2,5-diaziridinyl-1,4-benzoquinones was prepared as potential CNS antitumor agents. Activity was evaluated in the murine leukemia L1210 system. The diurethane derivative 9 was found to have significant activity in that system as well as in the intraperitoneal P388 and B16 tumor models. Marginal Lewis lung activity was observed. Reproducible activity was seen in the intracerebral L1210 and P388 systems. Multiple cures were observed in the murine ependymoblastoma brain tumor model. The effect of substituent type on aziridinylquinone activity is discussed.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1249812     DOI： 10.1021/jm00224a022

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  15 in total

Review 1.  Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis.

Authors:  Gudrun Fleischhack; Ulrich Jaehde; Udo Bode
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 2.  Diaziquone (AZQ).

Authors:  J F Bender; A J Grillo-Lopez; J G Posada
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

3.  Survival and cell cycle kinetics responses of Chinese hamster ovary cells, and clones of human adenocarcinoma of the stomach and astrocytoma to diaziquone (AZQ) in vitro.

Authors:  S C Barranco; G A Schechter; W R Boerwinkle; K A Howell; N H Rubin
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

4.  Superiority of PCNU over AZQ in the treatment of primary brain tumors: results of a prospective randomized trial (81-20) by the Brain Tumor Study Group.

Authors:  M G Malkin; S B Green; D P Byar; T A Strike; P C Burger; F S Vogel; D A Pistenmaa; M S Mahaley; J Ransohoff; W R Shapiro
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

5.  Response variability of human brain tumors to AZQ in tissue culture.

Authors:  P L Kornblith; L Rosa; J D Bona; J A Edwards; N Matuzic; A Hirschfeld; C Hawkins
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

6.  Stability of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ; NSC 224070) in aqueous solutions by high-performance liquid chromatography.

Authors:  A G Bosanquet; S B McLoughlin
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

7.  Thiol oxidation coupled to DT-diaphorase-catalysed reduction of diaziquone. Reductive and oxidative pathways of diaziquone semiquinone modulated by glutathione and superoxide dismutase.

Authors:  I D Ordoñez; E Cadenas
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

8.  Intracerebral chemotherapy in the 9L rat brain tumor model.

Authors:  B F Kimler; C Liu; R G Evans; R A Morantz
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

9.  Ureido-ethyl-imidazolines active against autochtonous diethylnitrosamine-induced epidermoid, papillary and adenocarcinomatous tumors of the respiratory tract of Syrian hamsters and against human bronchogenic carcinomas in nu/nu mice.

Authors:  A Marxer; K H Schmidt-Ruppin
Journal:  Experientia       Date:  1981-11-15

10.  A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.

Authors:  M C Chamberlain; M D Prados; P Silver; V A Levin
Journal:  J Neurooncol       Date:  1988-12       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.